Development and validation of a HPLC method for the determination of buprenorphine hydrochloride, naloxone hydrochloride and noroxymorphone in a tablet formulation

Talanta

Volumn 77, Issue 4, 2009, Pages 1415-1419

  Mostafavi, Ali ^a   Abedi, Ghazaleh ^b   Jamshidi, Ahmad ^b   Afzali, Daryoush ^a   Talebi, Mohammad ^b  

^a SHAHID BAHONAR UNIVERSITY OF KERMAN   (Iran)

^b IRAN POLYMER AND PETROCHEMICAL INSTITUTE   (Iran)

Author keywords

Buprenorphine hydrochloride; High performance liquid chromatography; Naloxone hydrochloride; Noroxymorphone; Tablet formulation

Indexed keywords

CHROMATOGRAPHIC ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH PRESSURE LIQUID CHROMATOGRAPHY; ORTHOPHOSPHORIC ACID;

BUPRENORPHINE HYDROCHLORIDE; CHROMATOGRAPHIC SEPARATIONS; NALOXONE HYDROCHLORIDE; NOROXYMORPHONE; PHARMACEUTICAL TABLETS; REVERSED-PHASE HIGH PERFORMANCE; SIMULTANEOUS DETERMINATIONS; TABLET FORMULATIONS;

POTASSIUM COMPOUNDS;

EID: 57249094205     PISSN: 00399140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.talanta.2008.09.024     Document Type: Article

References (19)

1. Walsh S.L., Preston K.L., Bigelow G.E., and Stitzer M.L. J. Pharmacol. Exp. Ther. 247 (1995) 361
2. Collins G.B., and McAllister M.S. Clev. Clin. J. Med. 74 (2007) 514
3. Lewis J.W. In: Cowan A., and Lewis J.W. (Eds). Buprenorphine: Combating Drug Abuse with a Unique Opioid (1995), Wiley-Liss, New York 151
4. Johnson R.E., Jaffe J.H., and Fudala P.J. J. Am. Med. Assoc. 267 (1992) 2750
5. Ling W., Wesson D.R., Charuvastra C., and Klett C.J. Arch. Gen. Psychiatry 53 (1996) 401
6. Chiang C.N., and Hawks R.L. Drug Alcohol Depend. 70 (2003) S39
7. Everhart E.T., Cheung P., Shwonek P., Zabel K., Tisdale E.C., Jacob III P., Mendelson J., and Jones R.T. Clin. Chem. 43 (1997) 2292
8. Lisi A.M., Kazlauskas R., and Trout G.J. J. Chromatogr. Biomed. Appl. 692 (1997) 67
9. Debrabandere L., Van Boven M., Laruelle L., and Daenens P. Anal. Chim. Acta 275 (1993) 295
10. Liu S.Y., Liu K.S., Kuei C.H., Tzeng J.I., Ho S.T., and Wang J.J. J. Chromatogr. B 818 (2005) 233
11. García-Fernández M.A., Fernández-Abedul M.T., and Costa-García A. Chromatographia 53 (2001) 704
12. Moody D.E., Slawson M.H., Strain E.C., Laycock J.D., Spanbauer A.C., and Foltz R.L. Anal. Biochem. 306 (2002) 31
13. Pirnay S., Hervé F., Bouchonnet S., Perrin B., Baud F.J., and Ricordel I. J. Pharm. Biomed. Anal. 41 (2006) 1135
14. Rodriguez-Rosas M.E., Lofwall M.R., Strain E.C., Siluk D., and Wainer I.W. J. Chromatogr. B 850 (2007) 538
15. The British Pharmacopoeia 2007, The Stationary Office (TSO), Health Ministry, London, 2006.
16. The United State Pharmacopoeia. 27th ed. (2004), The United States Pharmacopoeial Convection, Rockville, MD
17. http://www.usp.org/USPNF/submitMonograph/improveMon.html
18. Amanlou M., Khosravian P., Souri E., Dadrass O.G., Dinarvand R., Alimorad M.M., and Akbari H. Bull. Korean Chem. Soc. 28 (2007) 183
19. ICH guidelines Topic Q2 (R1) Validation of Analytical Procedures: Methodology, obtained from web site: www.emea.europa.eu/htms/human/ich/ichquality.htm.